Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 776 • 2013 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Modifies Chromatin Landscape and Amplifies Inflammatory Responses To Subsequent Stimuli In Synovial Fibroblasts
Angela Lee¹, Lionel B. Ivashkiv² and George D. Kalliolias¹, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Fibroblast-like synoviocytes (FLS) cross-talk with macrophages (Mf) during the course of rheumatoid arthritis (RA). Our group has shown that TNFa, primarily Mf-derived within synovium,…
Abstract Number: 166 • 2013 ACR/ARHP Annual Meeting
The Potential Role Of Protein Tyrosine Phosphatase Receptor D (PTPRD) Gene Copy Number Variation In Susceptibility To Rheumatoid Arthritis
Su Jin Yoo¹, Mi Kyoung Lim², Donghyuk Sheen³, In Seol Yoo⁴, Jinhyun Kim⁵, Seong Wook Kang⁴ and Seung-Cheol Shim⁶, ¹Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea, ²Medicine, Eulji University Hospital, Daejeon, South Korea, ³Rheumatology, Eulji University Hospital, Daejeon, South Korea, ⁴Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁵Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁶Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea
Background/Purpose: Since it is important to explore genetic variations associated with rheumatoid arthritis (RA), genome-wide association studies (GWAS) have led to the identification of RA…
Abstract Number: 2345 • 2013 ACR/ARHP Annual Meeting
Long-Term Targeted Safety Event Rates In RA Patients Following Initiation Of Rituximab: Interim Analysis From Sunstone Registry
Kenneth G. Saag¹, Kevin L. Winthrop², Kimberly Alexander³, Steven Francom⁴ and Daniel Furst⁵, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³Epidemiology, Genentech, Inc., South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA, ⁵Rheumatology, UCLA, Los Angeles, CA
Background/Purpose: Rituximab (RTX) is used for the treatment of rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti-TNF therapy (TNF-IR). Long-term safety…
Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting
Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Maria E. Suarez-Almazor² and Mahesh Bavineni³, ¹General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Internal Medicine, Louisiana State University Lafayette, Lafayette, LA
Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…
Abstract Number: 457 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamic Effect Of Intravenous Golimumab By Messenger Ribonucleic Acid Expression Profiling
Yauheniya Cherkas, Carrie Brodmerkel, Mark Curran and Sarah Lamberth, Janssen Research & Development, LLC., Spring House, PA

Background/Purpose: RA is a chronic systemic autoimmune disease resulting in joint inflammation and damage. Despite the current therapies available, only a small percentage of RA…
Abstract Number: 2346 • 2013 ACR/ARHP Annual Meeting
Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Vibeke Strand¹, Keith S. Kanik², Carol Connell², Bethanie Wilkinson², David Gruben² and Gene Wallenstein², ¹Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Participation, in particular work productivity, is increasingly recognized as…
Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Atsushi Ogata, Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…
Abstract Number: 403 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Biomarkers Of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Juan Chen¹ and Dana P. Ascherman², ¹Rheumatology, The First Afflicted Hospital of Xiamen University,, Xiamen,, China, ²Medicine/Rheumatology, University of Miami, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Asymptomatic, subclinical RA-associated…
Abstract Number: 2877 • 2013 ACR/ARHP Annual Meeting
Potential Of Integrating Human Genetics and Electronic Medical Records For Drug Discovery: The Example Of TYK2 and Rheumatoid Arthritis
Dorothee Diogo¹, Katherine P. Liao², Robert S. Fulton³, Robert R. Graham⁴, Jing Cui⁵, Jeffrey D. Greenberg⁶, Stephen Eyre⁷, John Bowes⁸, Annette T. Lee⁹, Dimitrios A. Pappas¹⁰, Joel M. Kremer¹¹, Anne Barton⁷, Marieke J.H. Coenen¹², Xavier Mariette¹³, Corrine Richard-Miceli¹⁴, Helena Canhão¹⁵, João E. Fonseca¹⁶, Niek de Vries¹⁷, Fina Kurreeman¹⁸, Ted R. Mikuls¹⁹, Yukinori Okada¹, Isaac Kohane²⁰, Joshua C. Denny²¹, Jane Worthington²², Soumya Raychaudhuri¹, Timothy W. Behrens²³, Michael F. Seldin²⁴, Peter K. Gregersen²⁵, Elaine R. Mardis³ and Robert M. Plenge²⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³The Genome Institute, Washington University School of Medicine, Saint Louis, MO, ⁴ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶NYU Hospital for Joint Diseases, New York, NY, ⁷Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁹Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ¹¹Center for Rheumatology, Albany Medical College, Albany, NY, ¹²Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹³Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹⁴Hôpital Bicêtre, Université Paris-sud, Paris, France, ¹⁵Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, ¹⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹⁷Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²⁰on behalf of i2b2 ; Brigham and Women's Hospital, Boston, MA, ²¹Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, ²²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²³Genentech, Inc, South San Francisco, CA, ²⁴Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA, ²⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Human genetics has the potential to identify promising drug targets for complex traits such as rheumatoid arthritis (RA). Genes with a series of disease-associated…
Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Matthew M. Seavey¹, Linglong Zou², Adam Clarke³, Anthony G. Doyle³, Roberta Weiss⁴, Aric Orbach⁵, Brad McIntyre⁶ and Merav Bassan⁷, ¹Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., West Chester, PA, ²GB&T, Teva Biopharmaceuticals, Rockville, MD, ³Discovery Biologics, Teva Pharmaceuticals, Inc., Sydney, Australia, ⁴Clinical Development, Teva Pharmaceuticals, Inc., Frazer, PA, ⁵Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., Netanya, Israel, ⁶Formulation, Teva Pharmaceuticals, Inc., West Cheater, PA, ⁷Teva R&D - Innovative Project Leadership, Teva Pharmaceuticals, Inc., Netanya, Israel
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
Abstract Number: 1432 • 2013 ACR/ARHP Annual Meeting
The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Patrice Cacoub Sr.³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁴Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁵Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ⁶Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹¹Rheumatology Department, CHU of ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Rhumatology departement, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ¹⁷Rheumatology Departement, Bicêtre University Hospital, Paris, France
Background/Purpose: Serious infections in patients with rheumatoid arthritis (RA) treated with rituximab (RTX) are slightly more frequent in common practice than in clinical trials. Morevover,…
Abstract Number: 400 • 2013 ACR/ARHP Annual Meeting
Parotid Ultrasound Abnormalities Among Rheumatoid Arthritis Patients: Prevalence and Clinical Correlates
Hong Yang¹, Doquyen H. Huynh², Arnold Ceponis³ and Arthur Kavanaugh⁴, ¹Rheumatology, UCSD, San Diego, CA, ²Rheumatology, UC San Diego School of Medicine, San Diego, CA, ³Medicine/Rheumatology, University of California San Diego, La Jolla, CA, ⁴University of California San Diego, San Diego, CA
Background/Purpose: Sjögren's syndrome (SS) occurs commonly among rheumatoid arthritis (RA) patients. It may be an indicator of, and even a contributor to, increased RA disease…
Abstract Number: 2810 • 2013 ACR/ARHP Annual Meeting
Follow-Up Testing Of Interferon-Gamma Release Assays For The Diagnosis Of Hidden Tuberculosis Infection In Patients Receiving Tumor Necrosis Factor Alpha Antagonists
Chan-Nam Son¹, Tae-Hwan Kim², Il-Hoon Sung³, Jae-Bum Jun² and Dae-Hyun Yoo², ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Orthopaedic surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Anti-tumor necrosis factor alpha (Anti-TNFα) therapy is often used in patients with rheumatic diseases who do not respond to conventional treatment. Risk of tuberculosis…
Abstract Number: 2295 • 2013 ACR/ARHP Annual Meeting
Mortality In Early Rheumatoid Arthritis Comparing Lithuania and Finland. A 13-Year Follow Up
Tuulikki Sokka¹, Sigita Stropuviene², Hannu Kautiainen³, Tuomas Rannio⁴ and Jolanta Dadoniene², ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Vilnius Univ, Vilnius, Lithuania, ³Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁴Jyvaskyla Central Hospital, Jyväskylä, Finland
Background/Purpose: Life span of patients with rheumatoid arthritis (RA) is reduced by 3-10 years compared to non-RA population. Only recent reports indicate improvements in survival…
Abstract Number: 1404 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking On Joint Physiology In Men and Mice
Caroline Ospelt¹, Giovanni Camici², Anna Engler³, Christoph Kolling⁴, Renate E. Gay⁵, Beat A. Michel⁶ and Steffen Gay¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Institute of Physiology, University of Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Schultess Clinic, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Smoking is a major risk factor for the development of anti-citrullinated protein antibodies positive rheumatoid arthritis (RA) in individuals who carry shared epitope alleles.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].